Trade agreements and generics: TRIPS and patent policy explained

Why does a life-saving medicine cost $10,000 in one country and $100 in another? It's often not about the ingredients or the factory costs. It's about the law. If you've ever wondered why generic medicines aren't available everywhere, the answer lies in a complex web of trade rules set nearly thirty years ago. These rules determine who owns a drug formula and who gets to sell it.

The backbone of this system is the TRIPS Agreement. This stands for the Trade-Related Aspects of Intellectual Property Rights Agreement. It is the global rulebook that dictates how countries protect patents. While designed to encourage innovation by giving companies time to profit, critics argue it has created massive barriers for poor nations trying to get affordable treatment. Let's unpack how this agreement changed the world and why it still matters today.

What is the TRIPS Agreement?

To understand the struggle for affordable drugs, we have to look at the history. Before the mid-1990s, there was no single global standard for patents. One country might protect a drug recipe (a product patent), while another only protected the method of making it (a process patent). This lack of uniformity meant generic manufacturers could legally produce cheaper versions of medicines using different manufacturing methods. Then came the Uruguay Round of trade negotiations.

From 1986 to 1994, wealthy nations pushed for stricter intellectual property standards to protect their industries. By January 1, 1995, the WTO(World Trade Organization) enforced these rules through the TRIPS framework. Every member state-164 of them-had to adopt minimum standards. The most impactful change was Article 33, which mandated a minimum 20-year patent protection period from the filing date. Suddenly, countries that previously allowed cheap generic competition had to close their borders to off-patent copies for two decades. The goal was consistency, but for developing nations, the result was an immediate loss of local manufacturing capacity and higher prices for essential treatments.

How Patents Changed the Market for Generics

Before TRIPS, many countries operated under systems that favored public health over profit margins. For instance, in the 1970s, India only required process patents. This meant you couldn't steal someone's secret way of making a chemical compound, but once that compound was known, others could manufacture it differently and sell the generic version. This fueled a booming Indian pharmaceutical sector that became the "pharmacy of the developing world," supplying HIV and antiretroviral drugs at tiny fractions of Western prices.

Under TRIPS, the landscape shifted dramatically. To comply with international law, India eventually had to transition to product patents by 2005. When this happened, studies published in the Lancet Oncology noted a spike in cancer drug prices, sometimes jumping by 300% to 500%. The logic was simple: once a company holds a patent on the drug molecule itself, no one else can touch it for 20 years without permission. During that monopoly period, prices remain high to recoup research and development costs, as argued by industry groups like the International Chamber of Commerce. However, for diseases like HIV/AIDS or malaria, which disproportionately affect low-income regions, those prices were often astronomical relative to local purchasing power.

The Compulsory License Exception

Did TRIPS completely shut down all hope for affordable access? Not quite. The architects of the deal knew that public health emergencies might require overrides. This led to Article 31, which establishes the concept of compulsory licensing. In short, this provision allows a government to authorize a third party to produce a patented medicine without the consent of the patent holder, usually in cases of national emergency or public non-commercial use.

In theory, this sounds like a safety valve. In practice, the mechanism is loaded with friction. To issue a compulsory license, a country generally has to prove it tried to negotiate a voluntary deal with the patent owner first-a step that takes months and signals political vulnerability. Furthermore, early interpretations of the agreement required that licensed production be primarily for the domestic market. This created a loophole disaster for countries like Rwanda or Botswana, which lacked the factories to produce the drugs themselves. They needed to import generics made elsewhere, but the exporting country also had to grant permission. It wasn't until a 2005 amendment, known as the "Paragraph 6 Solution," that cross-border trade became legally clearer. By 2016, records showed only one shipment of malaria medicine had actually moved successfully through this channel. The rules exist, but the red tape makes them nearly unusable.

Doha Declaration and Public Health Rights

The pressure on developing nations built up quickly after implementation. By 2001, the crisis in sub-Saharan Africa regarding HIV treatment forced a reckoning within the WTO. Leaders gathered in Doha, Qatar, to discuss the intersection of trade and health. The resulting Doha Declaration on the TRIPS Agreement and Public Health was a landmark victory for activists and patient groups.

The declaration explicitly stated that "the TRIPS Agreement does not and should not prevent members from taking measures to protect public health." It confirmed that countries had the right to prioritize people over profits when issuing licenses. However, it stopped short of rewriting the core patent terms. It clarified the ambiguity but didn't remove the financial burden. For many policymakers, it was a moral win that lacked the teeth to stop aggressive litigation. Pharmaceutical giants continued to monitor compliance closely, and lawsuits against generic producers remained a frequent threat, keeping governments hesitant to exercise their rights even when legally permitted.

Real-World Battles: Brazil, India, and Beyond

Theoretical agreements meet real-world consequences when countries actually try to follow them. Brazil serves as a prime example. In 2000, the US government initiated legal action against Brazil under Section 301 of its Trade Act, threatening sanctions over the country's plan to produce generic antiretrovirals. The US cited the need to protect American patent holders. Under international pressure, the US eventually withdrew the complaint, but the message sent to other nations was chilling: push too hard, and face trade retaliation.

South Africa faced a similar ordeal in 1998. After passing the Medicines and Related Substances Control Amendment Act to allow cheaper imports, forty pharmaceutical companies sued the South African government in Pretoria. The lawsuit lasted three years and attracted massive global condemnation before being withdrawn. It highlighted how multinational corporations could use legal resources to intimidate nations. Meanwhile, India became the primary manufacturing hub for generic exports following the 2005 patent transition. Because India granted licenses to smaller local firms before the deadline, it maintained a buffer stock of knowledge and capacity. Today, despite restrictions, India remains crucial for the supply chains of organizations like the Global Fund to Fight AIDS, Tuberculosis and Malaria.

TRIPS Plus: Going Beyond the Basics

If complying with the baseline TRIPS agreement was difficult for poor nations, many found an even higher wall called "TRIPS Plus." Developed countries began signing bilateral free trade agreements that demanded protections exceeding the WTO standards. For example, while TRIPS sets the term at 20 years, many of these side deals extend data exclusivity periods to 5-8 years. This prevents regulators from accepting clinical trial data to approve generic versions even after a patent expires.

This phenomenon is prevalent in agreements negotiated by the US and EU with Asian and Latin American partners. According to analyses from the late 2010s, 85% of US free trade agreements contained provisions stricter than TRIPS requirements. This effectively extends monopolies further, pushing the availability of generics back even more. For a disease with a rapidly changing virus profile, delaying generic entry by just a few extra years can mean millions of unmet needs. Critics label this "evergreening," where minor tweaks to a drug formulation earn fresh patents, keeping competitors out indefinitely.

The COVID-19 Waiver Debate

The arrival of the pandemic in 2020 brought the topic of intellectual property back into the spotlight. With urgent demand for vaccines, diagnostics, and therapeutics, India and South Africa proposed a complete waiver of TRIPS enforcement for pandemic-related technologies. Over 100 WTO members supported the idea, citing the need to maximize production capacity globally.

The backlash from wealthier nations was swift and firm. The European Union, US, and Switzerland opposed a full waiver, arguing it would hurt future R&D investment. The compromise reached in June 2022 resulted in a partial exemption for COVID-19 vaccines only, leaving testing kits and treatments largely untouched. By 2023, a formal WTO agreement solidified these limited concessions. While symbolic, the debate revealed that the fundamental tension between patent rights and human survival remains unresolved. Even during a global emergency, the machinery of intellectual property law proved remarkably resistant to rapid dismantling.

Moving Forward: Innovating Without Barriers

As we move further into the 2020s, the conversation isn't just about waiving rules anymore; it's about structural reform. Models like the Medicines Patent Pool have emerged as middle-ground solutions. Established in 2010, this pool negotiates voluntary licenses with patent holders to allow generic manufacturers to scale up production. By 2022, it covered dozens of medicines for HIV, Hepatitis C, and tuberculosis, helping reach millions of patients in lower-income settings.

However, voluntary pools rely on the goodwill of big pharma. Many advocates argue that relying on charity isn't sustainable for chronic diseases or neglected tropical conditions. The challenge for the next decade is balancing the need for incentive (so companies keep inventing) with the need for access (so people live). Whether that comes through stronger compulsory licensing frameworks, better technology transfer support from rich nations, or revised treaty terms, the gap between patent law and human health continues to widen in some corners of the globe.